PureSource Research began as an independent research initiative, arising from personal interest in chronic illness, immune function, and metabolic health, particularly in relation to tick-borne conditions.

The manuscripts below represent ongoing, independent research. They are not commissioned, sponsored, or peer-reviewed, and are shared for educational and research-modelling purposes only. Nothing on this page constitutes medical advice.

The research-use materials available through this site help support the ongoing costs of maintaining this research platform, including hosting, software, and related expenses. Below is an index of manuscript titles prepared to date, along with two representative papers available for review. Further papers will be published on an ongoing basis.

Manuscript index

1. Retatrutide and Chronic Lyme — Working Draft, Jul 2026

2. Lyme Complex as a Systems Failure, Not a Single Infection — Draft, Jul 2026

3. Reverse T3–Locked Hypometabolism as a Primary Failure Mode in Chronic Babesia and Lyme-Complex Illness — Draft, Jul 2026

4. Fever Incompetence and Failed Thermogenesis as Clinical Markers of Endocrine Lock in Babesia-Dominant Lyme-Complex Illness — Draft, Jul 2026

5. Night Repair Window — Working Draft, May 2026

6. Neuroimmune Stabilisation as a Recovery Window in Chronic Lyme-Complex Illness — Working Draft, May 2026

7. Asymmetric Antimicrobial Coverage in Multi-Pathogen Tick-Borne Disease: A Mechanistic Model of Trapped Affect — Draft, Apr 2026

8. Lead-Driven Enteric and Neuro-Metabolic Suppression as a Hidden Failure Mode in Lyme-Complex Disease: A Systems-Biology Hypothesis — Draft, Feb 2026

9. Early-Life Immune Perturbation as a Trigger for Hypometabolic Immune Lock in Genetically Vulnerable Systems — Working Draft, Jan 2026

10. Reverse T3 Lockout as a Pathological Failsafe: Thyroid Signalling Suppression in Chronic Hypometabolic Illness — Working Draft, Jan 2026

11. Threshold-Forcing and State Transition: Principles for Escaping Hypometabolic Immune Lock — Working Draft, Jan 2026

12. Hypometabolic Immune Lock as a Defended Systems Attractor in Chronic Illness — Working Draft, Jan 2026

13. The Microbiome as an Attractor Stabiliser in Hypometabolic Immune Lock States — Draft, Jan 2026

14. Neurodevelopmental Extensions of the Hypometabolic Immune Lock: Autism Spectrum Conditions as Early-Life Attractor Entrapment — Working Draft, Jan 2026

15. Folate Collapse as a Primary Initiator of Hypometabolic Immune Lock: A Competing–Convergent Hypothesis in MTHFR-Vulnerable Systems — Working Draft, Jan 2026

16. Reverse T3 Lockout as a Pathological Failsafe: A Systems Failure Mode in Chronic Babesia Infection — Working Draft, Jan 2026

17. SpO₂ as a Biomarker of Thyroid Lockout and Metabolic Gating in Babesia-Dominant Chronic Illness — Draft, Jan 2026

18. Cytokine Deadlock Hypothesis — Draft, Jan 2026

19. Reverse T3–Locked Hypometabolism as a Primary Failure Mode in Chronic Babesia and Lyme-Complex Illness: Implications for ME/CFS, Drug Failure, and Immune Reconstitution — Draft, Jan 2026

20. Pharmacodynamic Failure in Hypometabolic Hosts: Why Antimicrobials Fail in Babesia-Dominant Lyme-Complex Illness Despite Adequate Drug Exposure — Draft, Jan 2026

21. Synchronous Metabolic Windowing as a Requirement for Immune Reconstitution in Babesia-Dominant Lyme-Complex Illness — Draft, Jan 2026

22. Babesia as the Kingmaker Pathogen: Hypoxia-Driven Metabolic Permission Failure in Lyme-Complex Illness — Draft, Jan 2026

23. Failure of Effective T3 Signalling as a Locking Mechanism in Babesia-Dominant Lyme-Complex Illness — Draft, Jan 2026

24. T3 Signalling Failure in Lyme — Draft, Jan 2026

25. Endocrine Cost of Immune Reset — Working Draft, Dec 2025

26. Nasal Neuropeptide Immunomodulation — Working Draft, Dec 2025

27. From Immune Suppression to Immune Resolution: A Peptide-Based Alternative to JAK Inhibitors in Infection-Burdened ME/CFS and Lyme Complex — Working Draft, Dec 2025

28. Fibrosis in Lyme Complex — Working Draft, Dec 2025

29. ATRI Hypothesis: Neuroimmune Vulnerability, Methylation Stress, and Early-Life Immune Load as Predisposing Factors in Chronic Lyme Collapse — Working Draft, Dec 2025

30. Redox Interference in Lyme Complex: A Hypothesised Role of Excess Antioxidant Signalling in Blunting Antimicrobial and Antimalarial Efficacy — Working Draft, Dec 2025

31. Babesia–Dopamine–Melanin Interactions: A Hypothesis on Neurochemical Suppression and Neuropsychiatric Symptoms in Lyme Complex — Working Draft, Dec 2025

32. Babesia-Driven Neuro-Enteric Suppression: Gut–Brain Axis Inhibition in Chronic Infection States — Working Draft, Dec 2025

33. Bartonella and Psychiatric Syndromes: Neurovascular Injury, Neuroinflammation, and Behavioural Dysregulation — Working Draft, Dec 2025

34. Biofilm Disruption Effects in Lyme Complex: Inflammatory Amplification, Toxin Release, and System Destabilisation — Working Draft, Dec 2025

35. Cerebral Hypoperfusion in Lyme Complex: Vascular Dysfunction, Neuroinflammation, and Cognitive Impairment — Working Draft, Dec 2025

36. Lyme Complex as a Systems Failure, Not a Single Infection: Multi-Pathogen Load, Immune Manipulation, and Terrain Collapse — Working Draft, Dec 2025

37. Babesia-Driven Hypoxia: A Systems Model of Red Blood Cell Dysfunction, Microvascular Flow Impairment, and Metabolic Collapse in Lyme Complex — Working Draft, Dec 2025

38. Immune Paralysis in Lyme: Mechanisms of Pathogen-Driven Immune Suppression and System Failure — Working Draft, Dec 2025

39. ATRI Hypothesis – Neuroimmune Vulnerability, Methylation and Early-Life Immune Load (v0.1) — Working Draft, Dec 2025

40. Babesia Dopamine-Melanin Hypothesis (legacy draft) — Working Draft, Dec 2025

41. Redox Interference: High-Dose Antioxidants and Antimicrobial/Antimalarial Efficacy in Lyme-Complex Terrain Collapse — Working Draft, Dec 2025

42. Babesia Papers (working manuscript collection) — Working Draft, Dec 2025

43. Immune Paralysis in Lyme (legacy draft) — Working Draft, Dec 2025

44. Babesia-Driven Hypoxia Model (legacy draft) — Working Draft, Dec 2025

45. Cerebral Hypoperfusion Model (legacy draft) — Working Draft, Dec 2025

46. Babesia-Driven Hypoxia Hypothesis (legacy draft) — Working Draft, Dec 2025

47. Biofilm Disruption Effects (legacy draft) — Working Draft, Dec 2025

48. Bartonella and Psychiatric Syndromes (legacy draft) — Working Draft, Dec 2025

49. Babesia Neuro-Enteric Suppression (legacy draft) — Working Draft, Dec 2025

50. Beneficial Biofilm Hypothesis Update — Working Draft, Nov 2025

51. Leaky Gut Repair (ATRI Paper 2, V1) — Working Draft, Dec 2025

52. Post-Antibiotic Immunoreconstitution (ATRI Paper 4, V1) — Working Draft, Dec 2025

53. PureSource Paper 1 (Full Final Manuscript) — Draft, Dec 2025

54. Developmental Timing: Four-Lock Hypothesis — Draft, Dec 2025

55. Beneficial Biofilm Hypothesis (ATRI Paper 1, V2) — Draft, Dec 2025

56. Beneficial Biofilm Hypothesis with Figures (V4) — Draft, Dec 2025

57. Bartonella Hypothesis — Draft, Dec 2025

58. Hypoxia, Autonomic Function, Gut Motility and Babesia — Draft, Dec 2025

Dates are approximate and reflect the latest available project record. Duplicate titles denote distinct manuscript versions retained in the research archive.